You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

~ Buy the ZULRESSO (brexanolone) Drug Profile, 2024 PDF Report in the Report Store ~

ZULRESSO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zulresso patents expire, and when can generic versions of Zulresso launch?

Zulresso is a drug marketed by Sage Therap and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and twenty-one patent family members in thirty-one countries.

The generic ingredient in ZULRESSO is brexanolone. One supplier is listed for this compound. Additional details are available on the brexanolone profile page.

DrugPatentWatch® Generic Entry Outlook for Zulresso

Zulresso was eligible for patent challenges on June 17, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2029. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZULRESSO?
  • What are the global sales for ZULRESSO?
  • What is Average Wholesale Price for ZULRESSO?
Drug patent expirations by year for ZULRESSO
Drug Prices for ZULRESSO

See drug prices for ZULRESSO

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZULRESSO
Generic Entry Date for ZULRESSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZULRESSO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brigham and Women's HospitalPhase 4
Sage TherapeuticsPhase 1
Donald Jeffrey NewportPhase 4

See all ZULRESSO clinical trials

US Patents and Regulatory Information for ZULRESSO

ZULRESSO is protected by eight US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZULRESSO is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZULRESSO

Sulfoalkyl ether cyclodextrin compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Anticonvulsant activity of steroids
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING POSTPARTUM DEPRESSION

Neuroactive steroid formulations and methods of treating CNS disorders
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Neuroactive steroids, compositions, and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING POSTPARTUM DEPRESSION

Sulfoalkyl ether cyclodextrin compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Sulfoalkyl ether cyclodextrin compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Sulfoalkyl ether cyclodextrin compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Sulfoalkyl ether cyclodextrin compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting ZULRESSO

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZULRESSO

When does loss-of-exclusivity occur for ZULRESSO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 09241858
Patent: Sulfoalkyl ether cyclodextrin compositions
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0905080
Patent: Composições, processo para reparar uma composição e produto
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 02603
Patent: COMPOSITIONS DE CYCLODEXTRINE A GROUPEMENTS ETHER SULFOALKYLIQUE (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

Patent: 71879
Patent: COMPOSITIONS DE CYCLODEXTRINE A GROUPEMENTS ETHER SULFOALKYLIQUE (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

China

Patent: 1959508
Patent: Sulfoalkyl ether cyclodextrin compositions
Estimated Expiration: ⤷  Sign Up

Patent: 5288650
Patent: Sulfoalkyl ether cyclodextrin compositions
Estimated Expiration: ⤷  Sign Up

Patent: 4053423
Patent: 磺烷基醚环糊精组合物 (Sulfoalkyl ether cyclodextrin compositions)
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 1355
Patent: КОМПОЗИЦИИ НА ОСНОВЕ СУЛЬФОАЛКИЛЬНЫХ ЭФИРОВ ЦИКЛОДЕКСТРИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARATION THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 1000828
Patent: СОСТАВЫ НА ОСНОВЕ СУЛЬФОАЛКИЛЬНЫХ ЭФИРОВ ЦИКЛОДЕКСТРИНА
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 68269
Patent: COMPOSITIONS DE CYCLODEXTRINE À GROUPEMENTS ÉTHER SULFOALKYLIQUE (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

Patent: 63430
Patent: COMPOSITIONS D'ÉTHER SULFOALKYLE DE CYCLODEXTRINE (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 19883
Patent: 磺烷基醚環糊精組合物 (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 8956
Patent: תכשירי סולפואלקיל אתר ציקלודקסטרין (Sulfoalkyl ether cyclodextrin compositions)
Estimated Expiration: ⤷  Sign Up

Patent: 3654
Patent: תכשירי סולפואלקיל אתר ציקלודקסטרין (Sulfoalkyl ether cyclodextrin compositions)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 23144
Estimated Expiration: ⤷  Sign Up

Patent: 39721
Estimated Expiration: ⤷  Sign Up

Patent: 76828
Estimated Expiration: ⤷  Sign Up

Patent: 44548
Estimated Expiration: ⤷  Sign Up

Patent: 10539193
Estimated Expiration: ⤷  Sign Up

Patent: 12072160
Patent: SULFOALKYL ETHER CYCLODEXTRIN COMPOSITION
Estimated Expiration: ⤷  Sign Up

Patent: 15110671
Patent: スルホアルキルエーテルシクロデキストリン組成物 (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

Patent: 17019879
Patent: スルホアルキルエーテルシクロデキストリン組成物 (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

Patent: 18052991
Patent: スルホアルキルエーテルシクロデキストリン組成物 (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS)
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 2459
Patent: COMPOSICIONES DE ETER-SULFOALQUILICO-CICLODEXTRINA. (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS.)
Estimated Expiration: ⤷  Sign Up

Patent: 10004900
Patent: COMPOSICIONES DE ETER-SULFOALQUILICO-CICLODEXTRINA. (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 9290
Patent: SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1314803
Estimated Expiration: ⤷  Sign Up

Patent: 110010742
Patent: SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZULRESSO around the world.

Country Patent Number Title Estimated Expiration
Japan 2018052991 スルホアルキルエーテルシクロデキストリン組成物 (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS) ⤷  Sign Up
Australia 2018204865 ANTICONVULSANT ACTIVITY OF STEROIDS ⤷  Sign Up
China 114053423 磺烷基醚环糊精组合物 (Sulfoalkyl ether cyclodextrin compositions) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.